Showing 1 - 10 of 766
protection. We use new survey data from India, the results of interviews with industry, government and multinational institutions …
Persistent link: https://www.econbiz.de/10012471281
. Using India as an example, it then brings together information gathered from both published sources and personal interviews …
Persistent link: https://www.econbiz.de/10012472451
tuberculosis drug samples that claim to be made in India and were sold in Africa, India, and five mid-income non-African countries … in India or non-African countries. Since this finding is robust for manufacturer-drug fixed effects, one likely …
Persistent link: https://www.econbiz.de/10012458199
outbreak in India. Using a difference-in-differences strategy, we find that this upstream research shock caused multinational … firms selling antibiotics in India to reduce their market exposure. Surprisingly, this void was filled by domestic Indian …
Persistent link: https://www.econbiz.de/10012533389
In 1996, following an epidemic, Pfizer tested a new drug on 200 children in Muslim Nigeria. 11 children died while others were disabled. We study the effects of the disclosure, in 2000, of the deaths of Muslim children in the Pfizer trials on vaccine compliance among Muslim mothers. Muslim...
Persistent link: https://www.econbiz.de/10014372412
Proposed "delinking" legislation would prohibit Pharmacy Benefit Managers (PBMs) from being remunerated based on the rebates and discounts they negotiate for drug insurance plans serving Medicare beneficiaries. This policy would significantly change drug pricing and utilization and shift...
Persistent link: https://www.econbiz.de/10014372424
We study the effect of price caps on the provision of costly effort by pharmaceutical firms using variation in drug discounts generated by a price regulation program that allows eligible hospitals to purchase outpatient drugs at steep discounts. These discounts directly affect drug...
Persistent link: https://www.econbiz.de/10014512103
We examine the role of consumption externalities in the demand for pharmaceuticals at both the brand level and over a therapeutic class of drugs. These effects emerge when use of a drug by others affects its value, and/or conveys information abut efficacy and safety to patients and physicians....
Persistent link: https://www.econbiz.de/10012470978
Recent work linking the adoption of key organizational practices to productivity raises an important question: if adoption increases productivity so dramatically, why does adoption across an industry take so long? This paper explores this question in the context of one particularly interesting...
Persistent link: https://www.econbiz.de/10012471425
We examine the role of network effects in the demand for pharmaceuticals at both the brand level and for a therapeutic class of drugs. These effects emerge when use of a drug by others conveys information about its efficacy and safety to patients and physicians. This can lead to herd behavior...
Persistent link: https://www.econbiz.de/10012471776